search
Back to results

Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Telmisartan
Telmisartan/Hydrochlorothiazide
Placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • History of mild-to-moderate hypertension
  • Patients who fail to respond adequately to telmisartan monotherapy
  • Participants between 18 and 80 years of age
  • Ability to provide written informed consent

Exclusion Criteria:

  • Patients taking more than three anti-hypertensive medications at the screening visit
  • Pre-menopausal women (last menstruation ≤ 1 year prior to start of screening)

    • Who are not surgically sterile (hysterectomy, tubal ligation)
    • Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study
  • Any women:

    • Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 4)
    • Who is nursing
  • Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

    • SGPT (ALT) (serum glutamate pyruvate transaminase) or SGOT (AST) (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal
    • Serum creatinine > 2.3 mg/dL
  • Clinically relevant sodium depletion, hyperkalemia, or hypokalemia at baseline
  • Known or suspected secondary hypertension
  • Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
  • Congestive heart failure (CHF) (NYHA (New York Heart Association) class CHF III-IV)
  • Unstable angina within the past three months
  • Stroke within the past six months
  • Myocardial infarction or cardiac surgery within the past three months
  • PTCA (percutaneous transluminal coronary angioplasty) within the past three months
  • History of angioedema
  • Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
  • Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
  • Administration of digoxin or other digitalis-type drugs
  • Patients with insulin treated Type II diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10%
  • Known drug or alcohol dependency within the past one year period
  • Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
  • Patients receiving any investigational therapy within one month of signing the informed consent form. Patients who have participated in previous telmisartan studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
  • Known hypersensitivity to any component of the formulations
  • Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Telmisartan plus Hydrochlorothiazide

    Telmisartan

    Arm Description

    Outcomes

    Primary Outcome Measures

    Change from baseline in seated diastolic blood pressure (DBP) at trough

    Secondary Outcome Measures

    Change from baseline in seated systolic blood pressure (SBP) at trough
    Change from baseline in standing DBP and SBP at trough
    Blood pressure control (seated DBP < 90 mmHg)
    Systolic blood pressure response
    Number of patients with abnormal findings in physical examination
    Changes from baseline in heart rate
    Number of patients with abnormal changes in laboratory parameters
    Number of patients with abnormal changes in resting 12-lead ECG (electrocardiogram)
    Orthostatic changes in blood pressure
    Number of patients with adverse events

    Full Information

    First Posted
    June 26, 2014
    Last Updated
    July 7, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02177435
    Brief Title
    Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension
    Official Title
    An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    February 1999 (undefined)
    Primary Completion Date
    September 1999 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    Study to demonstrate that a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide (HCTZ) 12.5 mg (FDC 80/12.5) is superior to telmisartan 80 mg (Telm 80) alone in patients who failed to respond adequately to Telm 80 monotherapy in lowering seated trough diastolic blood pressure (DBP) after eight weeks of treatment.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    491 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Telmisartan plus Hydrochlorothiazide
    Arm Type
    Experimental
    Arm Title
    Telmisartan
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    Telmisartan
    Intervention Type
    Drug
    Intervention Name(s)
    Telmisartan/Hydrochlorothiazide
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Primary Outcome Measure Information:
    Title
    Change from baseline in seated diastolic blood pressure (DBP) at trough
    Time Frame
    Baseline (day 0), day 28, day 56
    Secondary Outcome Measure Information:
    Title
    Change from baseline in seated systolic blood pressure (SBP) at trough
    Time Frame
    Baseline (day 0), day 28, day 56
    Title
    Change from baseline in standing DBP and SBP at trough
    Time Frame
    Baseline (day 0), day 28, day 56
    Title
    Blood pressure control (seated DBP < 90 mmHg)
    Time Frame
    16 weeks
    Title
    Systolic blood pressure response
    Time Frame
    16 weeks
    Title
    Number of patients with abnormal findings in physical examination
    Time Frame
    Baseline (screening), day 0 and day 56
    Title
    Changes from baseline in heart rate
    Time Frame
    Baseline (screening), day -56, -28, 0, 28 and 56
    Title
    Number of patients with abnormal changes in laboratory parameters
    Time Frame
    Baseline (screening), day 0 and day 56
    Title
    Number of patients with abnormal changes in resting 12-lead ECG (electrocardiogram)
    Time Frame
    Baseline (screening), day 0 and day 56
    Title
    Orthostatic changes in blood pressure
    Time Frame
    Baseline (screening), day -56, -28, 0, 28 and 56
    Title
    Number of patients with adverse events
    Time Frame
    up to 16 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: History of mild-to-moderate hypertension Patients who fail to respond adequately to telmisartan monotherapy Participants between 18 and 80 years of age Ability to provide written informed consent Exclusion Criteria: Patients taking more than three anti-hypertensive medications at the screening visit Pre-menopausal women (last menstruation ≤ 1 year prior to start of screening) Who are not surgically sterile (hysterectomy, tubal ligation) Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study Any women: Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 4) Who is nursing Hepatic and/or renal dysfunction as defined by the following laboratory parameters: SGPT (ALT) (serum glutamate pyruvate transaminase) or SGOT (AST) (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal Serum creatinine > 2.3 mg/dL Clinically relevant sodium depletion, hyperkalemia, or hypokalemia at baseline Known or suspected secondary hypertension Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney Congestive heart failure (CHF) (NYHA (New York Heart Association) class CHF III-IV) Unstable angina within the past three months Stroke within the past six months Myocardial infarction or cardiac surgery within the past three months PTCA (percutaneous transluminal coronary angioplasty) within the past three months History of angioedema Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve Administration of digoxin or other digitalis-type drugs Patients with insulin treated Type II diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10% Known drug or alcohol dependency within the past one year period Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol Patients receiving any investigational therapy within one month of signing the informed consent form. Patients who have participated in previous telmisartan studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study Known hypersensitivity to any component of the formulations Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.261_U00-3112.pdf
    Description
    Related Info

    Learn more about this trial

    Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension

    We'll reach out to this number within 24 hrs